Table 1.
Vaccine formulations using model antigen ovalbumin (OVA) as antigen.
| Group No. (n = 10) | Adjuvant | Adjuvant Dose µg/50 µL | 
|---|---|---|
| 1 | None (OVA alone) | - | 
| 2 | SLA | 500 | 
| 3 | R848 | 5 | 
| 4 | CpG | 5 | 
| 5 | MPLA | 5 | 
| 6 | QS-21 | 5 | 
| 7 | Pam3CSK4 | 5 | 
| 8 | Poly(I:C) | 20 | 
| 9 | SLA + R848 | 500 + 5 | 
| 10 | SLA + CpG | 500 + 5 | 
| 11 | SLA + MPLA | 500 + 5 | 
| 12 | SLA + QS-21 | 500 + 5 | 
| 13 | SLA + Pam3CSK4 | 500 + 5 | 
| 14 | SLA + Poly(I:C) | 500 + 20 |